Which of the following drugs is most likely to cause hypoglycemia when used as a monotherapy in the treatment of type 2 diabetes ?
## **Core Concept**
The question tests the understanding of the pharmacological profiles of various antidiabetic drugs, particularly their effects on blood glucose levels. Type 2 diabetes management involves several classes of medications, each with a different mechanism of action and side effect profile.
## **Why the Correct Answer is Right**
Sulfonylureas, like **Glibenclamide (Glyburide)**, stimulate insulin release from the pancreatic beta cells. This insulin secretagogue action can lead to an excessive release of insulin, causing hypoglycemia, especially if the drug accumulates or if the patient's diet or glucose levels change unexpectedly. Sulfonylureas are known for their risk of inducing hypoglycemia as a side effect.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Metformin primarily works by decreasing hepatic glucose production and increasing insulin sensitivity. It does not typically cause hypoglycemia when used as monotherapy because it does not directly stimulate insulin secretion.
- **Option B:** Pioglitazone is a thiazolidinedione that enhances insulin sensitivity. Like metformin, it does not usually cause hypoglycemia when used alone because it does not directly increase insulin levels.
- **Option D:** Acarbose works by inhibiting intestinal alpha-glucosidases, delaying carbohydrate absorption. It can cause gastrointestinal side effects but is less likely to cause hypoglycemia as monotherapy since it does not affect insulin secretion directly.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that when managing type 2 diabetes, the risk of hypoglycemia is significantly higher with insulin secretagogues (like sulfonylureas) compared to other classes of antidiabetic drugs. This is crucial for selecting the right medication based on a patient's risk factors and lifestyle.
## **Correct Answer:** . Glibenclamide (Glyburide)